90 completed, 35 terminated, 26 recruiting, 16 unknown. 193 Phase 2, 44 Phase 1, 17 Phase 3.
Follow Stem Cell Transplantation: new trials by email Literature Review of Stem Cell Transplantation trials Research Report on Stem Cell Transplantation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus - Graft -Versus-host-disease | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 72 | 2026-11-01 | 2026-09-08 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2026-06-01 | 2026-09-03 | |
| Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD) Hematopoietic stem cell transplant (HSCT) - Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder | Phase 2 | Recruiting | Paul Szabolcs | 25 | 2026-05-04 | 2026-05-15 |
| Horizon Two: HR NDMM (MMRC-100) Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant - High Risk Newly Diagnosed Multiple Myeloma | Phase 2 | Recruiting | Multiple Myeloma Research Consortium | 300 | 2026-04-30 | 2026-10-02 |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan - Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-02-04 | 2026-10-19 |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2025-09-26 | 2026-07-20 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C - AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL) | Phase 2 | Recruiting | Center for International Blood and Marrow Transplant Research | 358 | 2025-07-25 | 2026-03-17 |
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2025-04-18 | 2026-06-29 |
| Intracerebral Autologous Stem Cell Therapy for Chronic Stroke Patients Stem cell Transplantation - Stroke, Stroke, Ischemic | Phase 2 | Recruiting | Hokkaido University Hospital | 8 | 2024-12-01 | 2025-01-24 |
| Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Biospecimen Collection, Chest Computed Tomography, Echocardiography - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 40 | 2024-08-01 | 2026-10-14 |
| Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma Elranatamab, Lenalidomide, Plerixafor - Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-07-17 | 2026-08-10 |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 216 | 2024-07-09 | 2026-10-23 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-27 |
| Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia Reinduction(4weeks), Cosolodation 1st(3weeks), Consolidation 2nd(3weeks) - Acute Lymphoid Leukemia | Phase 2 | Recruiting | Ho Joon Im | 90 | 2024-04-04 | 2026-07-29 |
Showing 20 of 193. Sign in to see all of them.
Leukemia, Myeloid, Acute (41) · Myelodysplastic Syndromes (35) · Multiple Myeloma (28) · Leukemia (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (26) · Lymphoma (24) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (20) · Hodgkin Disease (18) · Lymphoma, Non-Hodgkin (18) · Hematologic Neoplasms (16) · Leukemia, Lymphocytic, Chronic, B-Cell (16) · Graft vs Host Disease (12) · Lymphoma, Large B-Cell, Diffuse (12) · Leukemia, Myelomonocytic, Chronic (10) · Primary Myelofibrosis (10)
M.D. Anderson Cancer Center (46) · Masonic Cancer Center, University of Minnesota (19) · Fred Hutchinson Cancer Center (11) · National Cancer Institute (NCI) (11) · City of Hope Medical Center (8) · Royan Institute (6) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (6) · St. Jude Children's Research Hospital (6) · General Hospital of Chinese Armed Police Forces (4) · Stem Cells Arabia (4) · University of Michigan Rogel Cancer Center (4) · Washington University School of Medicine (4) · Baylor College of Medicine (3) · Medical College of Wisconsin (3) · National Heart, Lung, and Blood Institute (NHLBI) (3)
United States (149) · Iran (9) · China (6) · Italy (4) · Jordan (4) · Vietnam (3) · Canada (2) · Australia (1) · Egypt (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · Mexico (1) · New Zealand (1)
Hamid Gourabi, PhD (6) · Paul Orchard, MD (6) · Yago Nieto, MD, PHD (6) · Naoto Ueno, MD, PhD (5) · Nasser Aghdami, MD,PhD (5) · Margaret MacMillan, MD (3) · Neal Flomenberg, MD (3) · Partow Kebriaei, MD (3) · Uday R Popat (3) · Amir Ali Hamidieh, MD (2) · An Yihua, doctor (2) · Andrew Artz, MD (2) · Angela Smith, MD (2) · Gregory Hale, M.D. (2) · Gregory Yanik, MD (2)
PMID 21586746, PMID 28292947, PMID 28403842, PMID 38114596, PMID 12171484, PMID 18723429, PMID 19179301, PMID 19546405, PMID 19667400, PMID 20383216, PMID 20661232, PMID 20919852, PMID 21403127, PMID 21777972, PMID 21868572, PMID 21991976, PMID 22282904, PMID 22405058, PMID 22419704, PMID 22430088, PMID 22847303, PMID 25046834, PMID 25209445, PMID 25824692, PMID 26123356, PMID 26199392, PMID 26416896, PMID 27118452, PMID 27118571, PMID 27293053, PMID 28296863, PMID 28522110, PMID 28797783, PMID 29618479, PMID 31212080, PMID 31438885, PMID 32499241, PMID 32683126, PMID 32840230, PMID 32902182, PMID 33407794, PMID 33951890, PMID 34156440, PMID 34312462, PMID 34432869, PMID 34492682, PMID 34515338, PMID 34914826, PMID 35904231, PMID 36902217
P30CA016672 (5), P30CA033572 (5), U10CA180821 (4), U10CA031946 (2), U10CA032102 (2), U10CA180888 (2), U24CA076518 (2), 2009 (1), P01CA049639 (1), P01HL075462 (1), P01HL122173 (1), P30CA015704 (1), P30CA093373 (1), P30CA138292 (1), P50CA107399 (1)